Daewoong Pharmaceutical announced that Nabota, its botulinum toxin product, has surpassed 1 trillion Korean won (approximately $750 million USD) in cumulative lifetime sales. The milestone underscores robust demand for Nabota across Asia-Pacific and emerging markets, where it competes alongside Botox, Dysport, and regional alternatives.
Market
Daewoong's Nabota Crosses 1 Trillion Won in Cumulative Sales—Asian Toxin Gains Scale
South Korean neuromodulator reaches major sales milestone, signaling sustained demand outside North America.
1-YEAR MOVE
ABBV▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Nabota's 1 trillion won milestone reflects sustained demand for non-Allergan toxins in Asia-Pacific.
Nabota's success reflects both strong brand recognition in South Korea and Japan, and successful market penetration in Southeast Asia and China. While Nabota remains largely absent from U.S. practices, the milestone signals that non-Allergan/Galderma toxins can achieve substantial scale in international markets. For U.S. practice owners, the data reinforces that the global neuromodulator market is increasingly fragmented, with regional players building defensible positions outside North America.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.